The theory was vividly validated in our clinical cohort, as DLBCL patients with concurrent PI3K activation and IQGAP3 upregulation actually had an exceptionally excellent survival outcome. This evidence concerns the gene IQGAP3 and diffuse large B-cell lymphoma.